Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease
- 31 December 2001
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 172 (2), 433-436
- https://doi.org/10.1006/exnr.2001.7814
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive DeclineJAMA, 2000
- Cerebrospinal fluid levels of amyloid β-peptide1–42, but not tau have positive correlation with brain glucose metabolism in humansNeuroscience Letters, 1999
- Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairmentNeuroscience Letters, 1999
- Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progressionAnnals of Neurology, 1999
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- Mild cognitive impairment — an early stage of Alzheimer’s disease?Published by Springer Nature ,1998
- Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's diseaseNeurology, 1997
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s DiseaseJournal of Neuroscience, 1996
- Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's diseaseAnnals of Neurology, 1995
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984